UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

Follow-up after curative treatment for oral squamous cell carcinoma. A critical appraisal of the guidelines and a review of the literature

European journal of surgical oncology, 2018-05, Vol.44 (5), p.559-565

2018

Link zum Volltext

Verfügbarkeit prüfen

146 Huge Decrease in Risk of Breast Cancer Relapse in the Netherlands over the Last 3 Decades

European journal of cancer (1990), 2012-03, Vol.48, p.S82-S83

2012

Link zum Volltext

Verfügbarkeit prüfen

248P The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2- advanced breast cancer patients: A study of the Dutch SONABRE registry

Annals of oncology, 2021-09, Vol.32, p.S468-S469

2021

Link zum Volltext

Verfügbarkeit prüfen

179P Time trends in overall survival and systemic therapy in patients with HR+/HER2- advanced breast cancer: A study of the SONABRE registry

Annals of oncology, 2022-05, Vol.33, p.S209-S209

2022

Link zum Volltext

Verfügbarkeit prüfen

180P A doubling in overall survival of patients with de novo HER2+ advanced breast cancer in the Netherlands

Annals of oncology, 2022-05, Vol.33, p.S210-S210

2022

Link zum Volltext

Verfügbarkeit prüfen

Patterns of recurrence following definitive chemoradiation for patients with proximal esophageal cancer

European journal of surgical oncology, 2021-08, Vol.47 (8), p.2016-2022

2021

Link zum Volltext

Verfügbarkeit prüfen

Oncologic management of ampullary cancer: International survey among surgical and medical oncologists

Surgical oncology, 2022-09, Vol.44, p.101841-101841, Article 101841

2022

Link zum Volltext

Verfügbarkeit prüfen

201P The implementation of first-line pertuzumab and the impact on overall survival in patients with de novo HER2+ metastatic breast cancer in the Netherlands in 2008-2017: A population-based cohort study

ESMO open, 2024-05, Vol.9, p.103223, Article 103223

2024

Link zum Volltext

Verfügbarkeit prüfen

105P Real-world systemic treatment choices and survival outcomes of patients diagnosed with non-metastatic high-risk HR+/HER2- breast cancer in the Netherlands

ESMO open, 2023-05, Vol.8 (1), p.101329, Article 101329

2023

Link zum Volltext

Verfügbarkeit prüfen

Treatment and survival of patients diagnosed with high-risk HR+/HER2− breast cancer in the Netherlands: a population-based retrospective cohort study

ESMO open, 2024-05, Vol.9 (5), p.103008-103008, Article 103008

2024

Link zum Volltext

Verfügbarkeit prüfen

202P Complete response rates, treatment patterns and survival outcomes in patients treated with first-line pertuzumab-based therapy in HER2-positive advanced breast cancer: A SONABRE study

ESMO open, 2024-05, Vol.9, p.103224, Article 103224

2024

Link zum Volltext

Verfügbarkeit prüfen

A national comparative effectiveness study to assess definitive chemoradiation regimens in proximal oesophageal squamous cell cancer

Annals of oncology, 2019-10, Vol.30, p.v295

2019

Link zum Volltext

Verfügbarkeit prüfen

761P - A national comparative effectiveness study to assess definitive chemoradiation regimens in proximal oesophageal squamous cell cancer

Annals of oncology, 2019-10, Vol.30, p.v295-v295

2019

Link zum Volltext

Verfügbarkeit prüfen

A real-life study on everolimus plus exemestane therapy in a cohort of HR-positive, HER2-negative postmenopausal advanced breast cancer patients; A study of the SOutheast Netherlands Advanced BREast cancer (SONABRE) Registry

European journal of cancer (1990), 2018-04, Vol.92, p.S113

2018

Link zum Volltext

Verfügbarkeit prüfen

394 (PB-027) - A real-life study on everolimus plus exemestane therapy in a cohort of HR-positive, HER2-negative postmenopausal advanced breast cancer patients; A study of the SOutheast Netherlands Advanced BREast cancer (SONABRE) Registry

European journal of cancer (1990), 2018-04, Vol.92, p.S113-S113

2018

Link zum Volltext

Verfügbarkeit prüfen

PCN517 VARIABILITY OF COST TRAJECTORIES OVER THE LAST YEAR OF LIFE; AN EXPLORATIVE STUDY IN PATIENTS WITH ADVANCED BREAST CANCER IN THE NETHERLANDS

Value in health, 2019-11, Vol.22, p.S538

2019

Link zum Volltext

Verfügbarkeit prüfen

219P Chemotherapy use and survival outcomes for patients diagnosed with metastatic hormone receptor-positive HER2-negative breast cancer, results from the Dutch SONABRE registry

ESMO open, 2023-05, Vol.8 (1), p.101408, Article 101408

2023

Link zum Volltext

Verfügbarkeit prüfen

94MO The prognostic and predictive effect of BMI in postmenopausal HR+ breast cancer patients receiving (extended) endocrine therapy: DATA trial analysis

ESMO open, 2023-05, Vol.8 (1), p.101318, Article 101318

2023

Link zum Volltext

Verfügbarkeit prüfen

233P Treatment pattern and outcomes for the first two lines of chemotherapy in patients diagnosed with metastatic triple-negative breast cancer, results from the Dutch SONABRE Registry

ESMO open, 2023-05, Vol.8 (1), p.101421, Article 101421

2023

Link zum Volltext

Verfügbarkeit prüfen

Towards evidence-based follow-up intervals for breast cancer survivors: Estimates of the preclinical detectable phase of contralateral second breast cancer

Breast (Edinburgh), 2019-06, Vol.45, p.70-74

2019

Link zum Volltext

Verfügbarkeit prüfen

A real-life study on the implementation and effectiveness of exemestane plus everolimus per hospital type in patients with advanced breast cancer. A study of the Southeast Netherlands Advanced Breast Cancer registry

Breast (Edinburgh), 2019-04, Vol.44, p.46-51

2019

Link zum Volltext

Verfügbarkeit prüfen

Screening for second primary melanomas: is it efficient?: Correspondence

British journal of dermatology (1951), 2013-05, Vol.168 (5), p.1133-1135

2013

Link zum Volltext

Verfügbarkeit prüfen

Screening for second primary melanomas: is it efficient?

British journal of dermatology (1951), 2013-05, Vol.168 (5), p.1133-1135

2013

Link zum Volltext

Verfügbarkeit prüfen

392P The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer on first-line endocrine therapy with or without a CDK 4/6 inhibitor

Annals of oncology, 2023-10, Vol.34, p.S345-S345

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Esmo Open
(7)
Annals Of Oncology
(6)
European Journal Of Cancer
(3)
Breast
(2)
British Journal Of Dermatology
(2)
European Journal Of Surgical Oncology
(2)
Surgical Oncology
(1)
Value In Health
(1)

3 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Follow-up after curative treatment for oral squamous cell carcinoma. A critical appraisal of the guidelines and a review of the literature

146 Huge Decrease in Risk of Breast Cancer Relapse in the Netherlands over the Last 3 Decades

248P The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2- advanced breast cancer patients: A study of the Dutch SONABRE registry

179P Time trends in overall survival and systemic therapy in patients with HR+/HER2- advanced breast cancer: A study of the SONABRE registry

180P A doubling in overall survival of patients with de novo HER2+ advanced breast cancer in the Netherlands

Patterns of recurrence following definitive chemoradiation for patients with proximal esophageal cancer

Oncologic management of ampullary cancer: International survey among surgical and medical oncologists

201P The implementation of first-line pertuzumab and the impact on overall survival in patients with de novo HER2+ metastatic breast cancer in the Netherlands in 2008-2017: A population-based cohort study

105P Real-world systemic treatment choices and survival outcomes of patients diagnosed with non-metastatic high-risk HR+/HER2- breast cancer in the Netherlands

Treatment and survival of patients diagnosed with high-risk HR+/HER2− breast cancer in the Netherlands: a population-based retrospective cohort study

202P Complete response rates, treatment patterns and survival outcomes in patients treated with first-line pertuzumab-based therapy in HER2-positive advanced breast cancer: A SONABRE study

A national comparative effectiveness study to assess definitive chemoradiation regimens in proximal oesophageal squamous cell cancer

761P - A national comparative effectiveness study to assess definitive chemoradiation regimens in proximal oesophageal squamous cell cancer

A real-life study on everolimus plus exemestane therapy in a cohort of HR-positive, HER2-negative postmenopausal advanced breast cancer patients; A study of the SOutheast Netherlands Advanced BREast cancer (SONABRE) Registry

394 (PB-027) - A real-life study on everolimus plus exemestane therapy in a cohort of HR-positive, HER2-negative postmenopausal advanced breast cancer patients; A study of the SOutheast Netherlands Advanced BREast cancer (SONABRE) Registry

PCN517 VARIABILITY OF COST TRAJECTORIES OVER THE LAST YEAR OF LIFE; AN EXPLORATIVE STUDY IN PATIENTS WITH ADVANCED BREAST CANCER IN THE NETHERLANDS

219P Chemotherapy use and survival outcomes for patients diagnosed with metastatic hormone receptor-positive HER2-negative breast cancer, results from the Dutch SONABRE registry

94MO The prognostic and predictive effect of BMI in postmenopausal HR+ breast cancer patients receiving (extended) endocrine therapy: DATA trial analysis

233P Treatment pattern and outcomes for the first two lines of chemotherapy in patients diagnosed with metastatic triple-negative breast cancer, results from the Dutch SONABRE Registry

Towards evidence-based follow-up intervals for breast cancer survivors: Estimates of the preclinical detectable phase of contralateral second breast cancer

A real-life study on the implementation and effectiveness of exemestane plus everolimus per hospital type in patients with advanced breast cancer. A study of the Southeast Netherlands Advanced Breast Cancer registry

Screening for second primary melanomas: is it efficient?: Correspondence

Screening for second primary melanomas: is it efficient?

392P The prognostic impact of BMI in patients with HR+/HER2- advanced breast cancer on first-line endocrine therapy with or without a CDK 4/6 inhibitor

Suchergebnisse filtern